- Home
- FGEN vs TPST Comparison
FGEN vs TPST Comparison
Compare FGEN & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- TPST
- Stock Information
- Founded
- FGEN 1993
- TPST 2011
- Country
- FGEN United States
- TPST United States
- Employees
- FGEN N/A
- TPST N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- TPST Health Care
- Exchange
- FGEN Nasdaq
- TPST Nasdaq
- Market Cap
- FGEN 33.5M
- TPST 33.0M
- IPO Year
- FGEN 2014
- TPST N/A
- Fundamental
- Price
- FGEN $7.80
- TPST $6.31
- Analyst Decision
- FGEN Strong Buy
- TPST Hold
- Analyst Count
- FGEN 1
- TPST 3
- Target Price
- FGEN $250.00
- TPST $30.00
- AVG Volume (30 Days)
- FGEN 56.2K
- TPST 72.3K
- Earning Date
- FGEN 08-05-2025
- TPST 08-07-2025
- Dividend Yield
- FGEN N/A
- TPST N/A
- EPS Growth
- FGEN N/A
- TPST N/A
- EPS
- FGEN N/A
- TPST N/A
- Revenue
- FGEN $6,996,000.00
- TPST N/A
- Revenue This Year
- FGEN N/A
- TPST N/A
- Revenue Next Year
- FGEN N/A
- TPST N/A
- P/E Ratio
- FGEN N/A
- TPST N/A
- Revenue Growth
- FGEN N/A
- TPST N/A
- 52 Week Low
- FGEN $4.50
- TPST $5.35
- 52 Week High
- FGEN $38.25
- TPST $28.34
- Technical
- Relative Strength Index (RSI)
- FGEN 67.08
- TPST 42.85
- Support Level
- FGEN $7.03
- TPST $6.57
- Resistance Level
- FGEN $5.73
- TPST $6.80
- Average True Range (ATR)
- FGEN 0.57
- TPST 0.25
- MACD
- FGEN 0.35
- TPST -0.06
- Stochastic Oscillator
- FGEN 100.00
- TPST 10.33
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.